{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neoplasm+Malignant&page=27", "query": { "condition": "Lung Neoplasm Malignant", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 1059, "total_pages": 106, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neoplasm+Malignant&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neoplasm+Malignant&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T21:05:41.299Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04698681", "title": "NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer", "Non-squamous Non-small-cell Lung Cancer", "Non-Squamous Non-Small Cell Neoplasm of Lung", "KEAP1 Gene Mutation", "NRF2 Mutation", "NFE2L2 Gene Mutation" ], "interventions": [], "intervention_types": [], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-01-19", "completion_date": "2022-02-09", "has_results": false, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 63, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04698681" }, { "nct_id": "NCT00629187", "title": "Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Central Nervous System Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2004-04", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-04-27", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00629187" }, { "nct_id": "NCT01933932", "title": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pegylated G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 510, "start_date": "2013-09-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-11-09", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 17, "location_summary": "Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933932" }, { "nct_id": "NCT03899792", "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Medullary Thyroid Cancer", "Infantile Myofibromatosis", "Infantile Fibrosarcoma", "Papillary Thyroid Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 36, "start_date": "2019-06-13", "completion_date": "2029-05", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 12, "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899792" }, { "nct_id": "NCT02376699", "title": "Safety Study of SEA-CD40 in Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Squamous Cell", "Hodgkin Disease", "Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Melanoma", "Neoplasm Metastasis", "Neoplasms, Head and Neck", "Neoplasms, Squamous Cell", "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Cancer Metastatic", "Non-small Cell Carcinoma", "Squamous Cell Cancer", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Neoplasm", "Lymphoma, Non-Hodgkin", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Intravenous (IV) SEA-CD40", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Subcutaneous (SC) SEA-CD40", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2015-02-28", "completion_date": "2023-04-14", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02376699" }, { "nct_id": "NCT06494046", "title": "Defining Musical Toxicity and Its Effect on Patient Well-being", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Carcinoma", "Esophageal Carcinoma", "Head and Neck Carcinoma", "Lung Carcinoma", "Malignant Brain Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-08-15", "completion_date": "2025-05-19", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06494046" }, { "nct_id": "NCT04500600", "title": "Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13378, "start_date": "2020-06-11", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04500600" }, { "nct_id": "NCT01185639", "title": "Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-Small-Cell Lung Carcinoma", "Liver Cancer", "Adrenal Cancer" ], "interventions": [ { "name": "stereotactic body radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 29, "start_date": "2010-08", "completion_date": "2016-06-27", "has_results": true, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 2, "location_summary": "Wilmington, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01185639" }, { "nct_id": "NCT00004930", "title": "Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 2, "location_summary": "New York, New York • Columbus, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004930" }, { "nct_id": "NCT04975256", "title": "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplasm of Colon", "Malignant Neoplasm of Lung", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-07-28", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-11-15T21:05:41.299Z", "location_count": 4, "location_summary": "St Louis, Missouri • Cleveland, Ohio • Houston, Texas + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975256" } ] }